{
    "data": [
        {
            "id": "4396648",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-29T15:09:09-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Pharmaceuticals: Humira LOE Coming At Right Time For Potential Blockbuster Etrasimod",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "306874",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4396648-arena-pharmaceuticals-humira-loe-coming-right-time-for-potential-blockbuster-etrasimod"
            }
        },
        {
            "id": "4396019",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-23T14:02:45-05:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Health Experts Suggest Pfizer's Vaccine Could Treat COVID-19 Variant",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "306048",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4396019-health-experts-suggest-pfizers-vaccine-treat-covidminus-19-variant"
            }
        },
        {
            "id": "4394574",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-14T09:37:40-05:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: More Growth For Inclacumab",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "304746",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4394574-global-blood-therapeutics-growth-for-inclacumab"
            }
        },
        {
            "id": "4393755",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-09T03:08:41-05:00",
                "isLockedPro": false,
                "commentCount": 70,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Is Worth The Risk For A Vaccine Payoff",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103970",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "304137",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4393755-pfizer-is-worth-risk-for-vaccine-payoff"
            }
        },
        {
            "id": "4393119",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-05T09:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 86,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Coronavirus Vaccine Playing Out, Still Inexpensive And Offering A High Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "303600",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4393119-pfizer-coronavirus-vaccine-playing-out-still-inexpensive-and-offering-high-yield"
            }
        },
        {
            "id": "4393071",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-04T14:37:21-05:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Murphy's Law Applies To Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "303607",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4393071-murphys-law-applies-to-pfizer"
            }
        },
        {
            "id": "4392067",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-30T12:12:24-05:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: A 'New' Growth Foundation In Genomic Medicine",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24084",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "302470",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4392067-pfizer-new-growth-foundation-in-genomic-medicine"
            }
        },
        {
            "id": "4390798",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-21T07:16:38-05:00",
                "isLockedPro": false,
                "commentCount": 51,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Upside From COVID-19 Vaccine Could Dissipate",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "301712",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4390798-pfizer-upside-from-covidminus-19-vaccine-dissipate"
            }
        },
        {
            "id": "4390472",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-19T18:20:41-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: 40% Discount On A Billion-Dollar Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105040",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "301365",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4390472-global-blood-therapeutics-40-percent-discount-on-billion-dollar-drug"
            }
        },
        {
            "id": "4387242",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-10T09:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 63,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Goldilocks Plays For A World After Trump And Covid",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "300054",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4387242-3-goldilocks-plays-for-world-after-trump-and-covid"
            }
        },
        {
            "id": "4387272",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-10T08:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vaccine Developments Knock Election News Off Front Page - Scott Martin Joins Alpha Trader",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105447",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "579361",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4387272-vaccine-developments-knock-election-news-off-front-page-scott-martin-joins-alpha-trader"
            }
        },
        {
            "id": "4380512",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-22T07:47:31-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Pharmaceuticals: H1 2021 Is A Good Time To Consider The Stock Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40101",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "297596",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4380512-arena-pharmaceuticals-h1-2021-is-good-time-to-consider-stock-again"
            }
        },
        {
            "id": "4379158",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-15T08:30:07-04:00",
                "isLockedPro": false,
                "commentCount": 89,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Inexpensive Income Stock With A Corona Vaccine Kicker",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "296559",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4379158-pfizer-inexpensive-income-stock-corona-vaccine-kicker"
            }
        },
        {
            "id": "4378484",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-11T04:01:56-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Reports Data, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "295796",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4378484-pfizer-reports-data-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4377077",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-30T17:27:59-04:00",
                "isLockedPro": false,
                "commentCount": 395,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "COVID-19 Vaccine Race Heats Up: Moderna Faces Off Against Pfizer And BioNTech",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "294590",
                            "type": "sentiment"
                        },
                        {
                            "id": "294591",
                            "type": "sentiment"
                        },
                        {
                            "id": "294592",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4377077-covidminus-19-vaccine-race-heats-up-moderna-faces-off-against-pfizer-and-biontech"
            }
        },
        {
            "id": "4377046",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-30T14:50:56-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Back On Track After A Lost Decade",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103182",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "294575",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4377046-pfizer-back-on-track-after-lost-decade"
            }
        },
        {
            "id": "4376956",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-30T04:37:26-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Vaccine Portfolio To Benefit From Co-Circulation Concerns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "294208",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4376956-pfizers-vaccine-portfolio-to-benefit-from-co-circulation-concerns"
            }
        },
        {
            "id": "4374650",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-16T10:24:38-04:00",
                "isLockedPro": false,
                "commentCount": 71,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Interesting, But Not My First Pick Of The Pharmas",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "292598",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4374650-pfizer-interesting-not-first-pick-of-pharmas"
            }
        },
        {
            "id": "4372162",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-02T15:27:31-04:00",
                "isLockedPro": false,
                "commentCount": 204,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Who Is Ahead In The COVID-19 Vaccine Race?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "290847",
                            "type": "sentiment"
                        },
                        {
                            "id": "290848",
                            "type": "sentiment"
                        },
                        {
                            "id": "290849",
                            "type": "sentiment"
                        },
                        {
                            "id": "290850",
                            "type": "sentiment"
                        },
                        {
                            "id": "290851",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4372162-who-is-ahead-in-covidminus-19-vaccine-race"
            }
        },
        {
            "id": "4370492",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-24T15:55:16-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Stock May Be Heading For A Big Breakout",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71685",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "289597",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4370492-pfizers-stock-may-be-heading-for-big-breakout"
            }
        },
        {
            "id": "4370079",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-21T04:24:39-04:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "More Pfizer/BioNTech Data On Their Actual Vaccine Candidate",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "289186",
                            "type": "sentiment"
                        },
                        {
                            "id": "289185",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4370079-pfizer-biontech-data-on-actual-vaccine-candidate"
            }
        },
        {
            "id": "4369933",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-20T11:44:23-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Investment Risk Diminishing As Oxbryta Outperforms",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "288976",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4369933-global-blood-therapeutics-investment-risk-diminishing-oxbryta-outperforms"
            }
        },
        {
            "id": "4368366",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-13T12:24:41-04:00",
                "isLockedPro": false,
                "commentCount": 83,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Pfizer's 4% Yield Is Your Best Covid-19 Vaccine Play",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103213",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "288062",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4368366-why-pfizers-4-percent-yield-is-your-best-covidminus-19-vaccine-play"
            }
        },
        {
            "id": "4367241",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-10T16:39:26-04:00",
                "isLockedPro": false,
                "commentCount": 128,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "T Cell Responses To Coronavirus Vaccines Are In The Interest Of National Security",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56012",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "287515",
                            "type": "sentiment"
                        },
                        {
                            "id": "287516",
                            "type": "sentiment"
                        },
                        {
                            "id": "287517",
                            "type": "sentiment"
                        },
                        {
                            "id": "287518",
                            "type": "sentiment"
                        },
                        {
                            "id": "287549",
                            "type": "sentiment"
                        },
                        {
                            "id": "287521",
                            "type": "sentiment"
                        },
                        {
                            "id": "287522",
                            "type": "sentiment"
                        },
                        {
                            "id": "287523",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4367241-t-cell-responses-to-coronavirus-vaccines-are-in-interest-of-national-security"
            }
        },
        {
            "id": "4361321",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-28T10:47:35-04:00",
                "isLockedPro": false,
                "commentCount": 329,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer/BioNTech COVID-19 Vaccine: A Reality Check",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "285550",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4361321-pfizer-biontech-covidminus-19-vaccine-reality-check"
            }
        },
        {
            "id": "4356124",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-29T08:01:50-04:00",
                "isLockedPro": false,
                "commentCount": 185,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: It's A Whole New Ballgame",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20449",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "281638",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4356124-pfizer-whole-new-ballgame"
            }
        },
        {
            "id": "4355806",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-26T06:48:21-04:00",
                "isLockedPro": false,
                "commentCount": 123,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Is A Buy Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "79365",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "281243",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4355806-pfizer-is-buy-now"
            }
        },
        {
            "id": "4351039",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-30T04:17:08-04:00",
                "isLockedPro": false,
                "commentCount": 76,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Set Limit Orders No Higher Than $33.94",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "277722",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4351039-pfizer-set-limit-orders-no-higher-33_94"
            }
        },
        {
            "id": "4349376",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-21T15:14:25-04:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: A Post Spinoff Dividend Growth Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105636",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "276304",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4349376-pfizer-post-spinoff-dividend-growth-opportunity"
            }
        },
        {
            "id": "4343288",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-05T17:43:43-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: With Or Without A COVID-19 Vaccine, The Stock Is A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103213",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273864",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4343288-pfizer-without-covidminus-19-vaccine-stock-is-buy"
            }
        },
        {
            "id": "4340366",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-28T11:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 83,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Adam Feuerstein Talks COVID-19 Treatments And Vaccines On Alpha Trader",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105447",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "579361",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4340366-adam-feuerstein-talks-covidminus-19-treatments-and-vaccines-on-alpha-trader"
            }
        },
        {
            "id": "4338589",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-20T14:05:31-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Key Catalysts Remain As The Search For Clinical Benefit Continues",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "269212",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338589-global-blood-therapeutics-key-catalysts-remain-search-for-clinical-benefit-continues"
            }
        },
        {
            "id": "4336954",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-10T00:32:34-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Braftovi Approval, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "269713",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4336954-pfizers-braftovi-approval-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4334077",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-25T08:18:24-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Eucrisa Label Expansion, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "267259",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4334077-pfizer-eucrisa-label-expansion-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4333377",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-21T00:27:40-04:00",
                "isLockedPro": false,
                "commentCount": 99,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Is A Buy Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "100856",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "266205",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4333377-pfizer-is-buy-now"
            }
        },
        {
            "id": "4332848",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-18T17:40:03-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Pharmaceuticals: Buy The Dip Ahead Of Catalyst-Rich 2020 And 2021",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "265975",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4332848-arena-pharmaceuticals-buy-dip-ahead-of-catalyst-rich-2020-and-2021"
            }
        },
        {
            "id": "4330524",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-08T17:54:59-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer At Attractive Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104820",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "264003",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4330524-pfizer-attractive-valuation"
            }
        },
        {
            "id": "4330509",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-08T13:57:23-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Nothing Exciting Yet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105567",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "264204",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4330509-global-blood-therapeutics-nothing-exciting-yet"
            }
        },
        {
            "id": "4321497",
            "type": "article",
            "attributes": {
                "publishOn": "2020-02-05T04:48:16-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Looks Attractive Heading Into Merger With Pfizer's Upjohn",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101336",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "259992",
                            "type": "sentiment"
                        },
                        {
                            "id": "259993",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4321497-mylan-looks-attractive-heading-merger-pfizers-upjohn"
            }
        },
        {
            "id": "4320476",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-31T06:14:39-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Misses Target, Soft Guidance, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "258802",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4320476-pfizer-misses-target-soft-guidance-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4317188",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-15T20:59:40-05:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Dividend Payout Is Well-Protected",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "254611",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4317188-pfizers-dividend-payout-is-well-protected"
            }
        }
    ]
}